Gynecologic Cancer News

Cancer drugs that received accelerated approval from the FDA gained regular approval significantly faster if their confirmatory trials demonstrated meaningful clinical benefits, according to results of a retrospective study.

Cancer mortality gradually declined over the past 2-plus decades, although the rate slowed between 2019 and 2022, according to results of the Annual Report to the Nation on the Status of Cancer.

A grassroots organization that formed with the goal of recalibrating cancer care around patient needs issued guidance intended to improve the design of randomized phase 3 trials.

Partnering with dental clinics to offer HPV vaccines to eligible children and adolescents improved vaccination rates by more than 8 percentage points in 1 year, according to a study published in Pediatrics.

Susan Domchek, MD, FASCO, has spent her entire career striving to stay one step ahead of cancer.

A common malaria drug could be repurposed to treat a variety of hematologic cancers and solid tumors, according to early study results.

Jonathan Kimmelman, PhD, has published multiple research papers and gotten into an inordinate number of debates about the clinical value of phase 1 trials.

VIENNA — Schistosoma haematobium can trigger cancer-related gene activity in the cervix, increasing the risk for cervical cancer, according to data presented at the ESCMID Global meeting.

In this video, Robert DeBernardo, MD, shares insight on antibody-drug conjugates as treatment for patients with cancer, a topic discussed at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.